Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute on Chronic Liver Disease (ACLF)

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical,
and commercial milestone payments, plus tiered royalties

May 31, 2023, Seattle, WA – Seal Rock Therapeutics, Inc., a clinical stage company
developing first-in-class and best-in-class kinase inhibitors, today announced it has
entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for
the development of an injectable formulation of SRT-015 for acute liver disease,
including Acute-on-Chronic Liver Failure (ACLF).
‍
Under the agreement, Seal Rock Therapeutics is eligible for payments up to €100
million, including regulatory, clinical, and commercial milestone payments, plus tiered
royalties.
‍
SRT-015, a highly optimized, second generation, liver-selective inhibitor of Apoptosis
Signal-reducing Kinase 1 (ASK1). It is being developed by Seal Rock Therapeutics, in
an oral formulation, as a treatment for severe acute alcoholic hepatitis as well as orphan
liver diseases and NASH.
‍
“We’re excited to announce this licensing deal with GENFIT that will accelerate the
development of an injectable formulation of our second-generation ASK1 inhibitor SRT-
015 for ACLF, a liver disease with high unmet need,” said Neil McDonnell, CEO of Seal
Rock Therapeutics. “At Seal Rock, we remain focused on initiating a Phase 2a trial of
oral SRT-015 for severe alcoholic hepatitis. We will also continue development of our
first-in-class LRRK2/ASK1 dual kinase inhibitors for Parkinson’s Disease and ALS.”

“Considering its liver-centric activity, the potential for multi-organ benefits and the
breadth of evidence supporting further development in ACLF, we strongly believe in the
potential of SRT-015,” said Pascal Prigent, CEO of GENFIT. “We are pleased to have
this opportunity to develop a new, injectable formulation of SRT-015 for Acute on
Chronic Liver Failure (ACLF).”
‍
‍About SRT-015
SRT-015 is a second-generation inhibitor of ASK1 developed internally by Seal Rock
Therapeutics. Optimized to overcome the liabilities of first-generation ASK1 inhibitors such as selonsertib, and with a liver-preferential distribution, SRT-015 is positioned as a
first-in-class product candidate for NASH and AH.

‍About Seal Rock Therapeutics​
‍Seal Rock Therapeutics is a privately held, clinical stage company based in Seattle
focused on developing first-in-class and best-in-class treatments for severe diseases
with limited or no available therapies. Seal Rock is led by an experienced management
team with a track record of successful drug discovery, development and
commercialization. The company’s clinical-stage lead product candidate, SRT-015, is a
highly optimized, first-in-class ASK1 inhibitor. Seal Rock is also developing preclinical-
stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for treatment of
neurodegenerative conditions such as Parkinson’s disease and ALS.
‍
For more information, please visit www.sealrocktx.com

Media Contact
‍Julie Rathbun
Rathbun Communications
‍Julie@rathbuncomm.com
‍206-769-9219